NY-ESO-1
Dose dependent effects of NY ESO 1 protein vaccine complexed with cholesteryl pullulan (CHP NY ESO 1) on immune responses and survival benefits of esophageal cancer patients
... full-length NY-ESO-1 protein with various ...the NY-ESO-1 protein in combination with the saponin adjuvant ISCOMATRIX ...of NY-ESO-1 induced more immune ...
10
Decitabine immunosensitizes human gliomas to NY ESO 1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway
... as NY-ESO-1 on glioma cells, which in turn can act as effective target molecules for T cell mediated ...of NY-ESO-1 TCR-trans- duced T lymphocytes through a Rickham reservoir ...
13
Immunohistochemical analysis of the expression of MAGE A and NY ESO 1 cancer/testis antigens in diffuse large B cell testicular lymphoma
... CTA exhibit a restricted normal tissue expression and a widespread expression in tumors of different histo- logical origin. Therefore, CTA may serve as targets for anti-cancer active specific immunotherapy [16]. To date, ...
6
<p>NY-ESO-1 Protein Vaccine Combining Alum, CpG ODN, and HH2 Complex Adjuvant Induces Protective and Therapeutic Anti-Tumor Responses in Murine Multiple Myeloma</p>
... vaccines. NY-ESO-1 is a member of the cancer/testis antigen (CTA) family expressed in diverse types of tumors including multiple myeloma, but not in normal adult tissues except for germ cells in ...
9
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells
... of 1 and tumor biopsies with positive staining for NY-ESO-1 in >25% of cells by immunohistochemistry underwent leukapheresis at either the PSBC or University of Washington General Clinical ...
10
Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor
... (Table 1) followed by adoptive transfer of NY-ESO- 1 c259 ...low NY-ESO-1 expression, defined as ≥1+ by IHC in ≥1% cells but not exceeding 2+ or 3+ in ≥50% ...
7
Autoantibodies to the NY-ESO-1 Tumor Antigen in Metastatic Melanoma: Sialylation of the Fc Region of Immunoglobulin G Induces Differential Expression Signatures of Inflammatory Molecules During Dendritic Cell Differentiation and Maturation
... for NY-ESO-1 studies were recruited through the high-dose interleukin-2 (IL-2) treatment unit at Aurora ...of 1/350 (range: 1/350-1/300,000) determined by enzyme-linked ...
18
Original Article Sperm protein 17, MAGE-C1 and NY-ESO-1 in hepatocellular carcinoma: expression frequency and their correlation with clinical parameters
... and NY-ESO-1, their expression profiles in HCC in our study were in accordance with previous ...and NY-ESO-1 in HCC, respective- ...that NY-ESO-1 was ...
7
Oral Vaccination with Attenuated Salmonella enterica Strains Encoding T-Cell Epitopes from Tumor Antigen NY-ESO-1 Induces Specific Cytotoxic T-Lymphocyte Responses
... of NY-ESO-1 is seen in approximately one-third to one-fourth of all cases of melanoma and lung, ovarian, esoph- ageal, bladder, and prostate cancers; and expression is often associated with ...
6
Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma
... demonstrated NY-ESO-1 staining in 76% of synovial sarcomas, as well as positivity in limited numbers of other sarcomas including ...of NY-ESO-1 staining (defined as 2–3+, > ...
8
Effective NY ESO 1–specific MHC II–restricted T cell receptors from antigen negative hosts enhance tumor regression
... (Table 1 and Supplemental Figure 1; supplemental material available online with this article; ...DR4/ NY-ESO-1 116 tetramer–stained and sorted cells after 1-week in vitro ...
13
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
... at 1+ staining by IHC, but not ≥50% of tumor cells expressing 2+ or 3+ by ...cohorts 1 and 2 received fludarabine 30 mg/m 2 /day × 4 days and cyclophosphamide 1800 mg/m 2 /day × 2 ...the ...
14
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
... receptor 1 (anti- PD-1) antibody, nivolumab, in preventing melanoma re- currence when administered following complete surgical ...Notably, NY-ESO-1 vaccine immunother- apy has also been ...
10
Original Article Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis
... All statistical analysis were performed with IBM SPSS Advanced Statistics 19.0 and MedCalc version 9 (MedCalcSoftware Broekstraat 52, B-9030 Mariakerke, Belgium). Parson × 2, con- tinuity correction × 2 and Fisher’s ...
6
Prevalence of plasma autoantibody against cancer testis antigen NY ESO 1 in HTLV 1 infected individuals with different clinical status
... antigen NY-ESO-1 in the peripheral blood of HTLV-1-infected individuals, irre- spective of clinical ...Since NY-ESO-1 is one of the most immunogenic CT antigens recognized ...
6
Cancer Testis Antigens and Immunotherapy: Expression of PRAME and NY-ESO-1 Predicts Survival in Soft Tissue Sarcoma
... patients, NY-ESO-1 expression was associated with lower grade and it was predictive of more favourable survival as shown before in a series of high-grade soft tissues sarcoma by Kakimoto et ...high ...
13
Multiepitope CD8+ T cell response to a NY ESO 1 peptide vaccine results in imprecise tumor targeting
... containing NY-ESO-1–derived peptides (Table 1) were synthesized as described (13, ...for 1 hour at room temperature, washed once in the same buffer, stained with anti-CD8 mAb (Becton ...
11
Independent review of ESO regulatory and incentives framework
... The ESO should balance the transmission system in the most cost efficient way, by removing information asymmetries, promoting competition through encouraging participation of existing and new participants into the ...
7
PROP: ESO s portal for reporting of operational problematics
... At the end of May 2012 the final component of the PROP was put in production, namely the ESO Operations Support Centre. This is the public face of the web application that allows the members of the scientific ...
7
The Event and Implied Situation Ontology (ESO): Application and Evaluation
... tity. These errors also resulted in 6 role duplications where subject and object of an assertion are identical while they should not. For one event, it caused conflicting assertions. 5.2.2. Quality checks of the ...
8